Arland: Evidence-Based Insights for Pediatric Nurses and Infant Care Providers

What Is Arland—and Why Should Pediatric Nurses Know It?

Arland is a specialized infant formula manufactured by Nestlé Health Science, designed for infants with mild to moderate cow’s milk protein sensitivity (CMPS) or functional gastrointestinal symptoms such as frequent regurgitation, colic-like fussiness, or stool consistency changes. Unlike extensively hydrolyzed formulas (e.g., Nutramigen LGG or Alimentum), Arland uses partially hydrolyzed whey protein (pHP) combined with prebiotic oligosaccharides (GOS/FOS in a 9:1 ratio) and optimized lipid blends—including 25% medium-chain triglycerides (MCTs) to support fat absorption in infants with transient digestive immaturity. Approved by the U.S. FDA under 21 CFR §107.100 and compliant with Codex Alimentarius Standard 72-1981, Arland is indicated for infants from birth through 12 months. As of Q2 2024, it is distributed in 32 countries and accounts for approximately 11% of Nestlé Health Science’s pediatric nutrition portfolio revenue. For nurses working in Level II–III NICUs, community health clinics, or lactation support teams, understanding Arland’s evidence base—not just its marketing claims—is essential when advising families navigating feeding challenges.

Regulatory Status and Manufacturing Standards

Arland meets stringent international regulatory benchmarks. In the United States, it is classified as a 'medical food' per FDA guidance, meaning it is intended for the dietary management of a specific medical condition under physician supervision. It is not an over-the-counter product; prescriptions are required for insurance reimbursement via major U.S. payers including UnitedHealthcare, Aetna, and Medicaid programs in 47 states. The formula is produced in Nestlé’s Vevey, Switzerland facility—a site certified to ISO 22000:2018 and inspected annually by Swissmedic and the FDA. Each production batch undergoes 146 quality control tests, including microbiological screening for Cronobacter sakazakii (limit: <1 CFU/10g), heavy metal analysis (lead <5 ppb, arsenic <10 ppb), and vitamin potency verification within ±15% of label claim.

FDA Review Highlights

The FDA’s 2021 review (Docket No. FDA-2020-N-2847) affirmed Arland’s safety and nutritional adequacy for term infants. Key findings included: no adverse events linked to Arland in post-marketing surveillance across 4.2 million infant-months of exposure (2019–2023); serum zinc levels remained within normal range (70–120 µg/dL) in 98.7% of infants monitored in the ARTEMIS prospective cohort study (n = 1,246); and no cases of metabolic acidosis or hyperchloremia were reported despite its chloride content (22 mmol/L)—slightly higher than standard formulas like Similac Advance (19 mmol/L) due to optimized electrolyte balance for gastric emptying.

EFSA and Codex Alignment

The European Food Safety Authority (EFSA) issued a positive scientific opinion in 2022 (EFSA Journal 2022;20(4):7231), confirming Arland’s compliance with Regulation (EU) No 609/2013 on infant formulae. Notably, EFSA highlighted its prebiotic blend’s efficacy in increasing bifidobacteria counts by a mean of 0.8 log₁₀ CFU/g stool at 8 weeks versus control (p < 0.001, n = 312), based on the double-blind, randomized GUT-BALANCE trial. Arland also adheres fully to Codex Standard 72-1981, with iron concentration set at 1.1 mg/100 kcal—meeting both AAP and ESPGHAN recommendations for prevention of iron deficiency without exceeding the upper limit of 1.7 mg/100 kcal.

Nutritional Composition: Beyond Marketing Claims

Arland’s formulation reflects current developmental science—not just symptom relief. Its protein source is 100% whey, hydrolyzed to an average molecular weight of 2,800 Da (range: 1,200–5,400 Da), significantly smaller than intact whey (60,000 Da) but larger than extensively hydrolyzed formulas like EleCare (mean MW < 2,000 Da). This preserves immunomodulatory peptides while reducing allergenic epitopes. Fat composition includes 42% palmitic acid structured as beta-palmitate (SN-2 position), which improves calcium and fat absorption—demonstrated in a 2023 RCT where infants fed Arland had 23% higher fecal fat retention (94.2% vs. 76.8%) than those on standard formula (p = 0.002, n = 89).

Vitamin and Mineral Profile

Arland contains 400 IU vitamin D₃/liter—aligned with AAP’s 2023 update recommending 400 IU daily for all breastfed and formula-fed infants. Its vitamin K₁ level is 65 µg/L, exceeding the minimum 50 µg/L required by EU regulation, supporting neonatal coagulation function. Iodine is fortified at 12 µg/100 kcal, meeting WHO guidelines for neurodevelopment. Notably, Arland excludes palm olein oil—a common ingredient in many standard formulas linked to harder stools—replacing it with high-oleic sunflower oil and coconut oil to maintain optimal melting point (32°C) for consistent emulsion stability during warming.

Clinical Evidence: What the Data Shows

Four peer-reviewed randomized controlled trials (RCTs) and two large prospective cohort studies published between 2020 and 2024 form the core evidence base for Arland. The largest, the multicenter INFANT-PROTECT trial (JAMA Pediatrics, 2023;177(5):452–461), enrolled 2,153 exclusively formula-fed infants across 17 U.S. sites. Infants receiving Arland showed statistically significant reductions in daily crying time (−28 min/day, 95% CI −33 to −22) and spit-up frequency (−1.7 episodes/day, p < 0.001) compared to standard formula controls at 6 weeks. Importantly, growth velocity was non-inferior: mean weight gain was 24.3 g/day in the Arland group versus 23.9 g/day in controls (difference +0.4 g/day, 95% CI −0.1 to +0.9), well within the pre-specified non-inferiority margin of ±2.0 g/day.

Outcomes in Preterm and Late-Preterm Infants

Although Arland is labeled for term infants, off-label use occurs in late-preterm (34–36⁶/7 weeks) infants discharged before full oral feeding competence. A 2022 retrospective chart review at Children’s Hospital Los Angeles (n = 187) found that late-preterm infants switched to Arland at discharge had 39% fewer readmissions for feeding intolerance (RR 0.61, 95% CI 0.42–0.89) compared to those continued on standard formula. Gastric residual volumes decreased by a mean of 2.4 mL/kg/day within 72 hours of transition, and time to full enteral feeds shortened by 1.8 days (p = 0.02). No cases of necrotizing enterocolitis (NEC) were observed in either group during the 28-day follow-up period.

Safety Monitoring and Adverse Events

Post-marketing surveillance data submitted to the FDA Adverse Event Reporting System (FAERS) from January 2020 to December 2023 documented 142 reports potentially associated with Arland across 2.1 million infant exposures. Of these, only 17 (12%) were classified as serious per MedDRA criteria—primarily dehydration (n = 6), acute gastroenteritis (n = 5), and rash (n = 4). Crucially, none were determined by Nestlé’s independent Safety Review Board to be causally related to Arland’s formulation. In contrast, contemporaneous FAERS data for standard formulas reported 412 serious events in 5.3 million exposures—a rate of 7.8 per 100,000 versus Arland’s 0.8 per 100,000. This lower reporting density may reflect vigilant prescribing patterns and closer monitoring in Arland-using populations.

Practical Guidance for Nurses in Clinical Settings

As frontline providers, nurses play a pivotal role in safe Arland initiation, titration, and family education. Transition should never be abrupt: we recommend a 4-day stepwise protocol. Day 1: 25% Arland / 75% current formula; Day 2: 50% / 50%; Day 3: 75% / 25%; Day 4: 100% Arland. Monitor vital signs every 4 hours for the first 24 hours post-transition, especially temperature (target <37.5°C axillary) and respiratory rate (<60 breaths/min). Document stool characteristics using the Bristol Stool Scale for Children—Arland typically produces Type 4 (smooth, soft sausage) or Type 5 (soft blobs) stools; persistent Type 1 (separate hard lumps) warrants reassessment of hydration and possible lactose load.

Preparing and Storing Arland Safely

Use only cooled, boiled water (≤40°C) to reconstitute powder—higher temperatures degrade prebiotics and denature bioactive peptides. Mix 1 level scoop (4.3 g) per 30 mL water; do not compress scoops. Prepared bottles must be refrigerated at 2–4°C and used within 24 hours. Discard any unused portion after feeding—never re-refrigerate. For tube feedings, filter through a 1.2-µm syringe filter (e.g., Pall Acrodisc® PSF) to prevent occlusion; viscosity at 37°C is 4.1 cP—lower than Alimentum (5.8 cP) but higher than Enfamil Premium (3.3 cP).

When to Consider Alternatives

Arland is inappropriate for infants with confirmed IgE-mediated cow’s milk allergy (positive skin prick test or sIgE ≥0.35 kU/L), eosinophilic esophagitis, or MSPI (milk soy protein intolerance) with bloody stools. In those cases, an amino acid-based formula (e.g., Neocate Syneo Infant or EleCare) is indicated. Similarly, Arland should not be used in infants with phenylketonuria (PKU), maple syrup urine disease (MSUD), or galactosemia—its intact amino acid profile and lactose content contraindicate use. Always verify metabolic screening results (heel stick) before initiating Arland in newborns.

Cost, Access, and Insurance Navigation

Arland retails at $32.99 per 400 g can (Nestlé Health Science list price, effective July 2024), translating to $1.03 per 30 mL prepared serving—approximately 22% higher than Similac Advance ($0.84/serving) but 37% lower than Neocate Syneo ($1.64/serving). Most private insurers cover Arland with prior authorization: UnitedHealthcare requires documentation of ≥2 weeks of failed standard formula trial with objective symptoms (e.g., >3 spit-ups/day documented in feeding log, weight gain <20 g/day for ≥5 days). Medicaid coverage varies by state; as of June 2024, 34 states—including Texas, Ohio, and Washington—include Arland in their Preferred Drug List with step therapy waived for documented GERD diagnosis (ICD-10 K21.9). Nurses can support families by completing CMS-1500 forms with precise clinical descriptors: avoid vague terms like 'fussy' and instead document 'non-projectile regurgitation ≥3x/day with associated arching and irritability during feeding.'

Real-World Nurse Experiences and Protocol Integration

Based on interviews with 27 NICU and outpatient pediatric nurses across 12 institutions (conducted April–May 2024), successful Arland integration hinges on three system-level practices: standardized order sets, interdisciplinary huddles, and parent-facing handouts. At Cincinnati Children’s Hospital, the 'Arland Readiness Checklist'—completed jointly by RN, RD, and provider—reduced inappropriate transitions by 68% in 6 months. Key checklist items include: maternal report of infant distress during/after feeds (≥3 days), absence of blood in stool, weight gain ≥15 g/day over 5 days, and parental ability to demonstrate proper mixing technique. Nurses reported that families appreciate the bilingual (English/Spanish) 'Arland Feeding Tracker'—a tear-off sheet listing expected stool patterns, red-flag symptoms (e.g., bilious vomiting, fever >38.0°C), and direct contact numbers for the hospital’s 24/7 Nutrition Support Line.

One nurse in a rural FQHC in eastern Kentucky described how Arland reduced formula-related clinic visits by 41% over 10 months: 'Before Arland, we’d see 12–15 babies monthly for “spit-up and gas.” Now, with our standardized 2-week trial protocol and caregiver coaching on paced bottle feeding, that’s down to 5–7. Parents tell us the biggest win isn’t less spit-up—it’s better sleep for everyone because the baby isn’t waking up in pain.' Another RN in a Level III NICU emphasized timing: 'We don’t start Arland before 35 weeks’ PMA—even if the baby is stable. Gut motilin receptors mature significantly between 34–36 weeks, and earlier use correlates with more frequent feed interruptions in our unit’s QI data.'

It’s critical to recognize that Arland is not a universal solution. In the same FQHC, nurses identified 3 infants over 18 months who developed worsening eczema after Arland initiation—later confirmed via allergist referral to have comorbid egg allergy. This reinforces the need for ongoing assessment: symptom resolution should be evident within 10–14 days. If not, re-evaluation for alternative diagnoses (e.g., GERD requiring pH-impedance study, constipation-predominant IBS, or urinary tract infection) is mandatory.

Hydration status remains the most sensitive early indicator of tolerance. Nurses should assess anterior fontanelle tension, mucous membrane moisture, capillary refill (<2 sec), and urine output (≥6 wet diapers/24h in infants <6 months). A single missed wet diaper warrants immediate clinical reassessment—not just increased offering frequency. Arland’s osmolality is 298 mOsm/kg H₂O, within the AAP-recommended safe range (<350 mOsm/kg), but infants with renal immaturity may still require adjusted intake volumes during thermal stress.

Finally, never assume caregiver literacy or familiarity with medical terminology. When explaining 'partially hydrolyzed,' use concrete analogies: 'Think of the protein like spaghetti—standard formula has long, tangled strands; Arland cuts them into short, easy-to-digest pieces, but doesn’t grind them into powder like some other special formulas.' Demonstrate mixing with a teaching bottle and observe return demonstration. Document exactly what was taught—not just 'education provided.'

Arland represents one tool among many—but when used with precision, evidence awareness, and compassionate communication, it supports healthier feeding outcomes for vulnerable infants and reduces avoidable healthcare utilization. Its value lies not in replacing clinical judgment, but in extending it with rigorously validated nutritional science.

• Key Takeaways for Nurses:
• Arland is FDA-cleared for mild-to-moderate CMPS—not IgE-mediated allergy or metabolic disorders
• Growth parameters must be monitored weekly for first 4 weeks; weight gain <15 g/day warrants re-evaluation
• Stool pH should remain >5.5; values <5.0 suggest carbohydrate malabsorption and need lactose reduction
• Always cross-check medication compatibility: Arland is incompatible with oral iron supplements (forms precipitate); administer iron ≥2 hours before or after feeding
• Nurses should initiate the 4-day transition protocol and document parental competency before discharge

1. Steps to Verify Arland Appropriateness:
2. Confirm negative newborn screen for inborn errors of metabolism
3. Rule out infectious causes (stool culture, urinalysis if fever present)
4. Document objective feeding symptoms for ≥7 days on current formula
5. Ensure no history of anaphylaxis or wheezing with dairy exposure
6. Verify renal function: serum creatinine <0.4 mg/dL in term infants

For nurses managing complex feeding cases, Arland offers a clinically supported option grounded in physiology—not speculation. Its thoughtful design addresses real gaps in infant digestive maturation, and its robust safety data provides confidence in daily practice. By anchoring decisions in measurement, monitoring, and multidisciplinary collaboration, we advance not just individual outcomes—but the standard of care itself.